Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression-A Case Report

JCO Precis Oncol. 2021 May 3:5:PO.20.00436. doi: 10.1200/PO.20.00436. eCollection 2021.

Authors

Hardik Sheth¹, Prashant Kumar^{2

3

4}, Aditya Shreenivas⁵, Janani Sambath^{2

3}, Ramya Pragya¹, Chetan Madre¹, Nevitha Athikari¹, Hemant Khandare¹, Vishal Peshattiwar¹, Rajan Datar⁴, Sewanti Limaye¹

Affiliations

¹ Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India.
² Institute of Bioinformatics, Bangalore, India.
³ Manipal Academy of Higher Education (MAHE), Manipal, India.
⁴ Department of Research and Innovations, Datar Cancer Genetics Limited, Nasik, India.
⁵ Department of Medical Oncology, Medical College of Wisconsin, Milwaukee, WI.

No abstract available

Publication types

Case Reports

MeSH terms

Anilides / therapeutic use*
Antineoplastic Agents / therapeutic use*
Class I Phosphatidylinositol 3-Kinases / genetics
Humans
Male
Middle Aged
Mutation
Neoplasm Staging
Nitriles / therapeutic use*
Receptors, Androgen / biosynthesis
Salivary Ducts*
Salivary Gland Neoplasms / drug therapy*
Salivary Gland Neoplasms / genetics
Salivary Gland Neoplasms / metabolism
Salivary Gland Neoplasms / pathology
Thiazoles / therapeutic use*
Tosyl Compounds / therapeutic use*

Substances

Anilides
Antineoplastic Agents
Nitriles
Receptors, Androgen
Thiazoles
Tosyl Compounds
Alpelisib
bicalutamide
Class I Phosphatidylinositol 3-Kinases
PIK3CA protein, human